10-Q: Precipio Q2 Sees Income Amid Revenue Growth

Precipio, Inc. reported a net income of $74,000 for Q2 2025, driven by a 27% increase in net sales and non-recurring income, despite ongoing operating losses and significant accumulated deficit.

Summary

• Net sales for the three months ended June 30, 2025, increased by $1.2 million (27%) to $5.7 million compared to $4.4 million in the same period of 2024.
• Service revenue, net, for Q2 2025 increased by $1.2 million (31%) to $5.03 million, primarily due to a 19% increase in cases processed (3,692 cases in Q2 2025 vs. 3,099 in Q2 2024).
• Product revenue for Q2 2025 increased by $26,000 (4%) to $624,000.
• Gross profit for Q2 2025 was $2.4 million, up from $1.7 million in Q2 2024, with gross margin improving to 43% from 39%.
• Operating expenses increased by $0.3 million for Q2 2025, driven by higher stock-based compensation, general and administrative costs, and R&D expenses, partially offset by decreased sales and marketing costs.
• Net income for the three months ended June 30, 2025, was $74,000, a significant improvement from a net loss of $1.22 million in Q2 2024.
• This net income was substantially influenced by $0.9 million in non-recurring other income, including $0.8 million from Employee Retention Credits and $0.1 million from a gain on settlement of liabilities.
• For the six months ended June 30, 2025, net sales increased by $2.7 million (34%) to $10.6 million, with a 30% increase in cases processed (6,713 cases).
• Net loss for the six months ended June 30, 2025, was $810,000, an improvement from a $3.3 million net loss in the same period of 2024.
• As of June 30, 2025, the company had an accumulated deficit of $103.3 million and a working capital deficit of $0.3 million.
• Cash at the end of Q2 2025 was $1.13 million, down from $1.39 million at December 31, 2024.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $0.3 million, compared to net cash used of $0.17 million in the prior year period.
• The company has approximately $3.7 million available for future common stock sales under its 2023 Registration Statement with A.G.P./Alliance Global Partners (AGP).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company achieved net income in Q2 2025 and showed strong revenue growth and improved gross margins, these positives are significantly offset by the persistent 'going concern' doubt, substantial accumulated deficit, and the non-recurring nature of the Q2 income drivers. The underlying financial health remains challenged, requiring further capital or sustained operational profitability.

Positives

• Net sales increased significantly by 27% for the three months and 34% for the six months ended June 30, 2025, driven by a higher number of cases processed.
• Gross margin improved to 43% in Q2 2025 from 39% in Q2 2024, indicating better cost leverage from increased case volume.
• Achieved a net income of $74,000 for the three months ended June 30, 2025, a substantial turnaround from a $1.22 million net loss in the prior year quarter.
• Generated positive net cash from operating activities of $0.3 million for the six months ended June 30, 2025, compared to cash used in the prior year.
• Received $0.8 million in Employee Retention Credits, contributing to other income.
• Successfully settled a liability, resulting in a $0.1 million gain.
• Repaid the Business Loan Agreement in full, eliminating a 20% interest rate debt.

Negatives

• The company continues to operate with a significant accumulated deficit of $103.3 million as of June 30, 2025.
• A working capital deficit of $0.3 million as of June 30, 2025, indicates short-term liquidity challenges.
• Despite the Q2 net income, the company still reported a net loss of $810,000 for the six months ended June 30, 2025.
• The net income for Q2 2025 was largely due to non-recurring items (ERC and liability settlement), suggesting that underlying operations may still be unprofitable.
• The company's ability to continue as a going concern remains in substantial doubt, dependent on generating additional revenue and/or raising further financing.
• Cash balance decreased from $1.39 million at year-end 2024 to $1.13 million at June 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months, requiring additional revenue generation or financing.
• The company has incurred substantial operating losses and typically used cash in operating activities for several years.
• Changes in tax law, such as the One Big Beautiful Bill Act (OBBBA), could adversely affect the business and financial condition, including changes to R&D expense amortization.
• The healthcare industry is subject to complex and evolving laws and regulations, with potential for significant fines, penalties, or expulsion from government programs for non-compliance.
• Customer concentration risk exists, with Customer C accounting for 27% of net sales in Q2 2025 and 25% of accounts receivable as of June 30, 2025.
• The company is involved in legal proceedings, including a former employee's unfair dismissal claim, which, while not currently expected to be material, could have an adverse impact.
• Delinquency on outstanding accounts payable for certain vendors and suppliers could lead to legal action.

Future Outlook

The company's ability to continue as a going concern over the next twelve months is dependent on achieving its business plan, including generating additional revenue, and raising additional financing if needed. There is no assurance that these initiatives will be successful. The company is also assessing the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on its business, outlook, and financial statements, particularly regarding federal tax law changes related to R&D expenses.

Management Comments

• Management believes the company is in compliance with fraud and abuse regulations and other applicable government laws and regulations.
• Management does not currently expect the former employee's unfair dismissal case to have a material impact on its financial results.
• Management believes that utilizing its clinical lab to obtain samples and use equipment and staffing for product development, testing, and validation significantly reduces development costs and timelines, accelerating time to market.
• Management states that being the first user of every product developed allows for optimization of laboratory functions and provides significant credibility with customers.

Industry Context

Precipio operates in the cancer diagnostics sector of the healthcare biotechnology industry, focusing on addressing misdiagnoses through proprietary diagnostic products and services. The company's strategy of integrating CLIA-certified laboratories for R&D and clinical use allows for cost reduction and accelerated product development, a unique approach that could differentiate it from competitors. The reliance on global healthcare distributors like ThermoFisher, McKesson, Medline, and Cardinal Health for market access is a common and effective go-to-market strategy in the diagnostics industry. The impact of the Change Healthcare cyberattack highlights the broader industry's vulnerability to cybersecurity risks and the critical role of third-party billing services.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards.
• The company's gross margin of 43% in Q2 2025 is an improvement and suggests efficiency gains from increased case volume, which could be competitive within the specialized diagnostics market, though specific industry benchmarks are not provided.
• The ongoing 'going concern' doubt and accumulated deficit are significant deviations from the financial stability typically expected of established industry players, indicating a need for substantial operational improvements or capital infusion to align with industry norms for sustainable growth.

Corporate Governance

Legal Proceedings

• A former employee has brought a legal proceeding in San Antonio, Texas, alleging unfair dismissal and seeking monetary damages. The company disputes these allegations and intends to defend itself vigorously, not currently expecting a material financial impact.
• CPA Global claimed approximately $0.2 million for patent maintenance services rendered on February 6, 2017, but has not filed claims. A liability of less than $0.1 million is recorded.
• The company is subject to numerous federal, state, and local healthcare laws and regulations, including those related to licensure, accreditation, government healthcare program participation, reimbursement, and fraud and abuse. Violations could result in significant fines, penalties, or expulsion from programs.

Related Party Transactions

• The company's Chief Executive Officer provided a personal guaranty for the $250,000 Business Loan and Security Agreement with Altbanq Lending LLC, which has since been repaid in full.

Stakeholder Impact

• Shareholders: Potential dilution from future common stock sales under the AGP agreement and warrant exercises. The net income in Q2 2025 is positive, but the going concern risk remains a concern for investment value.
• Employees: Stock-based compensation is a component of their remuneration. The company's ability to continue as a going concern directly impacts job security.
• Customers: Increased case processing indicates growing service delivery. The company's use of its own products in its CLIA labs aims to improve customer support and product quality.
• Suppliers/Creditors: The company has been delinquent on accounts payable for certain vendors, posing a risk to supplier relationships. Repayment of the CHC assistance and the business loan indicates efforts to manage liabilities.
• Regulatory Authorities: The company's operations are subject to extensive healthcare laws and regulations, requiring ongoing compliance to avoid penalties.

Next Steps

• Continue efforts to generate additional revenue and achieve the business plan to address going concern issues.
• Actively evaluate the likelihood and timing of receiving the remaining $0.7 million balance of the Employee Retention Credit claim.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on the company's forecasted annual effective tax rate and overall financial statements.
• Make equal monthly payments of approximately $83,000 through January 2026 to settle the remaining balance of the CHC Temporary Assistance Program funds.

Key Dates

Recommendation

While Precipio demonstrated strong revenue growth and achieved a net income in Q2 2025, largely due to non-recurring items, the company still faces substantial doubt about its ability to continue as a going concern. The significant accumulated deficit and working capital deficit indicate persistent financial challenges. The recent warrant exercise provided a cash infusion, and the remaining availability under the AGP sales agreement offers a potential source of future capital. However, until the company demonstrates sustained profitability from core operations and resolves the going concern uncertainty, the stock remains a speculative investment. A 'hold' recommendation is appropriate for existing investors to monitor progress on operational efficiency and capital management, while new investors should exercise caution due to the high risk profile.

Keywords

Cancer diagnostics, Biotechnology, Healthcare, SEC filing, 10-Q, Financial results, Revenue growth, Net income, Operating loss, Going concern, Employee Retention Credit, CLIA laboratories, Pathology services, Diagnostic products, Medical technology, Corporate finance